Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced plans to publicly transfer its 100% stake in wholly-owned subsidiary Zhejiang Pharmaceutical Industry Co., Ltd. via a property rights exchange. The assessed value of the subsidiary stands at 392 million yuan, with a minimum listing price set at 430 million yuan. On November 10, 2025, the company submitted the listing application to Taizhou Property Rights Exchange Co., Ltd. The official listing period will run from November 11 to December 8, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments